Early and delayed effects of AST-120 on chronic cyclosporine nephropathy

Nephrology Dialysis Transplantation

Volumn 26, Issue 5, 2011, Pages 1502-1515

  Kim, Su Hyun ^a   Ghee, Jung Yeon ^b   Piao, Shangguo ^b   Han, Dong He ^b   Song, Ji Hyun ^b   Yoon, Hye Eun ^b   Choi, Bum Soon ^b   Kim, Jin ^b   Nishijima, Fuyuhiko ^c   Obara, Kazumi ^c   Ishikawa, Noriyuki ^c   Yang, Chul Woo ^b  

^a Chung Ang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c KUREHA CORPORATION   (Japan)

Author keywords

AST 120; chronic cyclosporine nephropathy; indoxyl sulphate; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AST 120; CYCLOSPORIN A; INDICAN; UREMIC TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EARLY INTERVENTION; EPITHELIAL MESENCHYMAL TRANSITION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SODIUM RESTRICTION; THERAPY DELAY; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARBON; CHRONIC DISEASE; CYCLOSPORINE; DISEASE PROGRESSION; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; KIDNEY DISEASES; MALE; MICROSPHERES; OXIDATIVE STRESS; OXIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955641646     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq640     Document Type: Article

References (47)

1. Myers BD, Ross J, Newton L et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705 (Pubitemid 14074555)
2. Bennett WM DeMattos A, Meyer MM et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100 (Pubitemid 26342797)
3. Capasso G Di Gennaro CI Della Ragione F et al. In vivo effect of the natural antioxidant hydroxytyrosol on cyclosporine nephrotox-icity in rats. Nephrol Dial Transplant 2008; 23: 1186-1195 (Pubitemid 351767503)
4. Ghee JY Han DH Song HK et al. The role of macrophage in the pathogenesis of chronic cyclosporine-induced nephropathy Nephrol Dial Transplant 2008; 23: 4061-4069
5. Niwa T, Miyazaki T, Hashimoto N et al. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992; 12: 201-206 (Pubitemid 23010389)
6. Tsubakihara Y, Takabatake Y, Oka K et al. Effects of the oral adsorb-ent AST-120 on tryptophan metabolism in uremic patients. Am JKid-ney Dis 2003; 41: S38-S41 (Pubitemid 36278343)
7. Schulman G, Agarwal R, Acharya M et al. A multicenter, rando-mized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am JKidney Dis 2006; 47: 565-577
8. Ueda H, Shibahara N, Takagi S et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860
9. Aoyama I, Shimokata K, Niwa T. Oral adsorbent AST-120 amelio-rates interstitial fibrosis and transforming growth factor-beta(1) ex-pression in spontaneously diabetic (OLETF) rats. Am J Nephrol 2000; 20: 232-241 (Pubitemid 30445321)
10. Sanaka T, Fujimoto K, Niwayama J et al. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal cre-atinine slope in patients with CRF. Am J Kidney Dis 2003; 41: S35-S37 (Pubitemid 36278342)
11. Niwa T, Tsukushi S, Ise M et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab 1997; 23: 179-184 (Pubitemid 27475340)
12. Nakagawa N, Hasebe N, Sumitomo K et al. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006; 26:455-461 (Pubitemid 44971736)
13. Shimoishi K, Anraku M, Kitamura K et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 2007; 24: 1283-1289 (Pubitemid 46870593)
14. Motojima M, Hosokawa A, Yamato H et al. Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated up-take. Br J Pharmacol 2002; 135: 555-563 (Pubitemid 34151188)
15. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chron-ic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99 (Pubitemid 39069904)
16. Djamali A. Oxidative stress as a common pathway to chronic tubu-lointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 2007; 293: F445-F455 (Pubitemid 47358116)
17. Cottone S, Palermo A, Vaccaro F et al. Oxidative stress and inflam-mation in long-term renal transplanted hypertensives. Clin Nephrol 2006; 66: 32-38 (Pubitemid 44043730)
18. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronicrenal failure. Semin Nephrol 2004; 24: 354-365 (Pubitemid 38900635)
19. Prakash J, de Borst MH, Lacombe M et al. Inhibition ofrenal rho kinase attenuates ischemia/reperfusion-induced injury. JAm Soc Ne-phrol 2008; 19: 2086-2097
20. Chung BH, Li C, Sun BK et al. Rosiglitazone protects against cyclo-sporine-induced pancreatic and renal injury in rats. Am J Transplant 2005; 5: 1856-1867 (Pubitemid 41039858)
21. Li C, Yang CW, Park CW et al. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int 2003; 63: 454-463 (Pubitemid 36126792)
22. Wu LL, Chiou CC, Chang PY et al. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9 (Pubitemid 37542453)
23. Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem 2007; 14: 339-351
24. Shoji T, Wada A, Inoue K et al. Prospective randomized study evalu-ating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal func-tion. Nephron Clin Pract 2007; 105: c99-c107 (Pubitemid 46215202)
25. Sanaka T, Sugino N, Teraoka S et al. Therapeutic effects of oral sor-bent in undialyzed uremia. Am JKidney Dis 1988; 12: 97-103
26. Owada A, Nakao M, Koike J et al. Effects oforal adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 1997; 63: S188-S190 (Pubitemid 28020467)
27. Motojima M, Nishijima F, Ikoma M et al. Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-469
28. Dou L, Jourde-Chiche N, Faure V et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Hae-most 2007; 5: 1302-1308 (Pubitemid 46902134)
29. Taki K, Niwa T Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chron-ic kidney disease. J Ren Nutr 2007; 17: 48-52 (Pubitemid 46014453)
30. Lee SH, Nam BY, Kang EW et al. Effects of an oral adsorbent on oxidative stress and fibronectin expression in experimental diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 2134-2141
31. Nakamura T, Sato E, Fujiwara N et al. Oral adsorbent AST-120 ame-liorates tubular injury in chronic renal failure patients by reducing pro-teinuria and oxidative stress generation. Metabolism 2010; Feb 26. [Epub ahead of print]
32. Yorioka N, Kiribayashi K, Naito T et al. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic Kidney disease. J Nephrol 2008; 21: 213-220
33. Konishi K, Nakano S, Tsuda S et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression ofrenal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 2008; 81: 310-315
34. Yorioka N, Ito T, Masaki T et al. Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure. J Int Med Res 2002; 30: 467-475 (Pubitemid 35282671)
35. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365 (Pubitemid 41376493)
36. Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007; 22: ix26-ix30
37. Yu HT Progression of chronic renal failure. Arch Intern Med 2003; 163: 1417-1429 (Pubitemid 36758914)
38. Aoyama I, Niwa T An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis 2001; 37: S7-S12 (Pubitemid 32048015)
39. Okada K, Matsumoto K, Takahashi S. Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in ne-phrectomized rats. Kidney Blood Press Res 2005; 28: 8-13 (Pubitemid 40069631)
40. Sanaka T, Akizawa T, Koide K et al. Protective effect of an oral ad-sorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 2004; 8: 232-240 (Pubitemid 38900430)
41. Sanaka T, Akizawa T, Koide K et al. Clinical analysis of renoprotec-tive responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis. Ther Apher Dial 2003; 7: 269-278 (Pubitemid 36753928)
42. Yoon HE, Yang CW Established and newly proposed mechanisms of chronic cyclosporine nephropathy Korean JIntern Med 2009; 24: 81-92
43. Abramowicz D, Del Carmen RM, Vitko S et al. Cyclosporine with-drawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. JAm Soc Nephrol 2005; 16: 2234-2240 (Pubitemid 41716457)
44. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with my-cophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-570 (Pubitemid 46376436)
45. Takemoto M, Tsuchida M, Konishi M et al. Effect oforal adsorbent AST-120 on cyclosporin absorption in rats. J Pharm Pharmacol 1997; 49: 657-660 (Pubitemid 27341709)
46. Yamagishi S, Nakamura K, Matsui T et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses 2007; 69: 666-668 (Pubitemid 47043236)
47. Ueda S, Yamagishi S, Takeuchi M et al. Oral adsorbent AST-120 de-creases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006; 12: 180-184 (Pubitemid 44646347)